FlexSpark was founded by a team of Biomedical Engineers out of the Georgia Institute of Technology with the goal of disrupting the standard of care for DVT prophylaxis. That standard is an uncomfortably bulky, noisy instrument called a Sequential Compression Device (SCD). The high rate of non-compliance, largely due to this technology’s shortcomings, results in 100,000 annual DVT related deaths, and costs hospitals and patients millions in the U.S. alone. To combat this problem, FlexSpark is developing an on-leg DVT prevention system that uses Electrical Muscle Stimulation (EMS) to improve circulation in the lower extremities. Their patented system reduces DVT related costs, increases patient compliance and comfort, and reduces muscle atrophy for improved patient outcomes.